FDA’s approval of an antidote to Boehringer Ingelheim GMBH’s Pradaxa should give the company a leg up on the other novel oral anticoagulants – given the continuing concerns about bleeding risks – but with a universal antidote coming soon from Portola Pharmaceuticals Inc., that advantage will be short-lived.
Boehringer’s Praxbind (idarucizumab) was granted accelerated approval Oct. 16 to reverse the anticoagulant effects of Pradaxa (dabigatran) for emergency surgery/urgent...